Article
21 May 2025
Teva And Alvotech Announce FDA Approval Of Interchangeability For SELARSDI (Ustekinumab-aekn) With STELARA (Ustekinumab)
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
20 Sep 2024
Celltrion Wins Brazilian Federal Tender For Trastuzumab For Fifth Consecutive Year
Article
10 Jul 2024
Fresenius Announces Launch Of Subcutaneous Formulation Of TYENNE (Tocilizumab-aazg) In The United States
Article
10 Jun 2024
Teva And Alvotech Announce Launch Of SIMLANDI (Adalimumab-ryvk) Injection In The U.S.
Article
08 May 2024
Accord BioPharma, Inc. Announces FDA Approval Of HERCESSI (Trastuzumab-strf)
Article
03 Apr 2024
Fresenius Kabi And Formycon Reach Settlement Agreement For Ustekinumab Biosimilar Candidate In Europe And Canada
Article
01 Mar 2024
FDA Approves XOLAIR To Treat Children And Adults With One Or More Food Allergies
Article
17 Jan 2024
Issue 43: PTAB Trial Tracker
Article
13 Nov 2023
Fresenius Kabi Launches TYENNE, The First Approved Tocilizumab Biosimilar In The European Union
Article
26 Jun 2023
Coherus To Acquire Surface Oncology
Article
23 May 2023
Biosimilar Clinical Trial Updates
Article
19 Apr 2023
Celltrion Confirms Bioequivalence For CT-P39 Against Xolair In Interim Results Of Phase 3 Study
Article
02 Feb 2023
Celltrion's Anticancer Biosimilar Debuts In Japan
Article
10 Jan 2023
Year In Review: Top Legal Developments Of 2022
Article
25 Nov 2022
Amneal Launches RELEUKO (filgrastim-ayow) In The United States
Article
28 Oct 2022
Request For Comments On USPTO Initiatives To Promote Generic Drug And Biosimilar Competition
Article
19 Sep 2022
Genentech And Samsung Bioepis Settle Bevacizumab Biosimilar Patent Dispute
Article
13 Jul 2022
Mylan Files New IPR Petitions On Aflibercept Patents
Article
08 Jun 2022
Sandoz Announces New Global "Act4Biosimilars" Initiative
Article
03 Jun 2022
Regeneron Files Antitrust Lawsuit Accusing Amgen Of Engaging In A Persistent Exclusionary Campaign To Deny Patients Access To Praluent®
